The mission of the Downes Lab is to better understand the relationships between antimicrobial pharmacokinetics/pharmacodynamics (PK/PD) and outcomes in vulnerable pediatric populations, including critically ill children and immunocompromised pediatric patients. The Lab engages in clinical and translational research to improve the safety and effectiveness of antimicrobials in children.
Dr. Downes has particular interests in the roles of biomarkers in the management of children with infectious diseases.
He has received funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to study the development and implementation of a personalized, target-oriented approach for dosing of vancomycin in critically ill children using population PK modeling and Bayesian dose adaptation.
Dr. Downes is also investigating novel approaches to therapeutic drug monitoring through the use of minimally invasive sampling techniques.